TransMedics Group (NASDAQ:TMDX) Trading Down 2.6% on Insider Selling

TransMedics Group, Inc. (NASDAQ:TMDXGet Rating) shares traded down 2.6% during trading on Friday following insider selling activity. The stock traded as low as $52.59 and last traded at $53.02. 1,942 shares were traded during mid-day trading, a decline of 100% from the average session volume of 440,990 shares. The stock had previously closed at $54.44.

Specifically, VP John F. Carey sold 2,956 shares of the stock in a transaction on Friday, June 24th. The shares were sold at an average price of $32.57, for a total transaction of $96,276.92. Following the completion of the transaction, the vice president now owns 379 shares in the company, valued at $12,344.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, VP John F. Carey sold 3,320 shares of the stock in a transaction on Monday, June 27th. The shares were sold at an average price of $32.59, for a total transaction of $108,198.80. Following the completion of the transaction, the vice president now owns 379 shares in the company, valued at $12,351.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP John F. Carey sold 2,956 shares of the company’s stock in a transaction on Friday, June 24th. The stock was sold at an average price of $32.57, for a total transaction of $96,276.92. Following the sale, the vice president now directly owns 379 shares in the company, valued at $12,344.03. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 183,905 shares of company stock worth $7,240,928. 8.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on TMDX. JPMorgan Chase & Co. raised shares of TransMedics Group from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $26.00 to $48.00 in a research report on Tuesday, August 2nd. Oppenheimer upped their price target on shares of TransMedics Group from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 2nd. Morgan Stanley upped their price target on shares of TransMedics Group from $34.00 to $37.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 3rd. Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $46.00 to $58.00 in a research report on Thursday, August 4th. Finally, Cowen increased their price objective on shares of TransMedics Group from $39.00 to $45.00 and gave the company an “outperform” rating in a research report on Tuesday, July 26th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $46.00.

TransMedics Group Trading Down 1.9 %

The firm has a market capitalization of $1.50 billion, a P/E ratio of -31.04 and a beta of 1.48. The business’s 50-day moving average is $42.74 and its 200 day moving average is $31.24. The company has a debt-to-equity ratio of 0.70, a current ratio of 4.18 and a quick ratio of 3.41.

TransMedics Group (NASDAQ:TMDXGet Rating) last released its quarterly earnings results on Monday, August 1st. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.09). TransMedics Group had a negative return on equity of 74.20% and a negative net margin of 92.76%. The business had revenue of $20.52 million for the quarter, compared to the consensus estimate of $16.26 million. During the same period in the prior year, the business posted ($0.39) earnings per share. As a group, analysts anticipate that TransMedics Group, Inc. will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently bought and sold shares of TMDX. Driehaus Capital Management LLC bought a new position in TransMedics Group during the second quarter worth about $19,338,000. Portolan Capital Management LLC acquired a new stake in TransMedics Group during the first quarter worth about $10,233,000. Millennium Management LLC acquired a new stake in TransMedics Group during the second quarter worth about $7,589,000. Next Century Growth Investors LLC grew its stake in TransMedics Group by 112.4% during the first quarter. Next Century Growth Investors LLC now owns 343,661 shares of the company’s stock worth $9,258,000 after buying an additional 181,842 shares in the last quarter. Finally, Emerald Advisers LLC grew its stake in TransMedics Group by 41.5% during the second quarter. Emerald Advisers LLC now owns 397,565 shares of the company’s stock worth $12,503,000 after buying an additional 116,612 shares in the last quarter. 81.46% of the stock is owned by institutional investors.

About TransMedics Group

(Get Rating)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Recommended Stories

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.